Skip to main content
Country-Specific Sites

First Safety Outcomes of Contireflex® Artificial Urinary Sphincter for Treating Male Incontinence

Author(s):
JOURNAL
The Journal of Urology
YEAR
DOI
https://www.auajournals.org/doi/10.1097/01.JU.0001009488.55564.85.16
View on Publisher Site

Abstract Short Summary

A 50-patient multi-center analysis showed ContiReflex® AUS is safe and effective, with no infections, no erosions, and a 98% 18-month device survival.

Abstract

Objective:

To assess the early safety profile and surgical outcomes of the Rigicon ContiReflex® artificial urinary sphincter in treating male stress incontinence.

Key Findings:

Among 50 patients, no infections or erosions occurred. One revision (2%) was required. A Kaplan–Meier analysis showed 98% device survival at 18 months.

Conclusion:

The Rigicon ContiReflex® AUS demonstrates a favorable early safety profile and is comparable to existing sphincter devices in treating male incontinence.

Clinical Relevance:

The ContiReflex® AUS offers a promising option for male incontinence treatment, with excellent early safety outcomes supporting broader clinical use.

Keywords

ContiReflex artificial urinary sphincter male incontinence AUS Rigicon device safety surgical outcomes urology

This publication is available through the external link above. See the abstract for a summary of the research.

Back to Clinical Evidence